Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Sağlık ve TıpOne-Off3y
Manifold MarketsKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreGüncel topluluk tahminiEvet 78.9%
Tahminciler
29
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
6 saat önce güncellendi
Guncelligini yitirmis26 Oca 24 00:13 UTC1 Oca 30 07:59 UTC
Trendler
Kurallar
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy.
- Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
- To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein).
- The gene therapy must be for humans.
- Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
